Financial Data and Key Metrics Changes - Globus Medical reported Q3 2025 sales of $769 million, a 22.9% increase year-over-year, with non-GAAP diluted earnings per share of $1.18, growing 42.6% compared to the prior year quarter [4][19][35] - Free cash flow reached a record $213.9 million for the quarter, contributing to a strong cash flow generation profile [4][33] - Adjusted EBITDA margin for the base Globus business was 35.3%, an increase of 435 basis points from the prior year quarter [5][21] Business Line Data and Key Metrics Changes - The U.S. spine business grew 9.6% as reported, continuing a trend of 32 weeks of consecutive growth [6][24] - Trauma business achieved a strong growth of 17.2%, marking the highest quarterly revenue since its inception [13][22] - Enabling technologies revenue declined 26.8% to $28 million, primarily due to lower sales of eGPS systems [8][22] Market Data and Key Metrics Changes - International spine business grew 5.6% as reported, with notable growth in EMEA and Asia-Pacific regions [11][12] - U.S. revenue during Q3 2025 was $617.6 million, growing 24.6% as reported, driven by strong performance in spine, trauma, and neuromonitoring [24][25] - Nevro contributed $99.3 million in revenue, growing 4.9% sequentially, indicating positive integration progress [15][23] Company Strategy and Development Direction - The company remains focused on partnering with surgeons to address unmet clinical needs and drive operational excellence [16] - There is a strategic shift towards flexible capital acquisition models, moving away from traditional cash sales to leasing and rental options [11][42] - The integration of Nevro is expected to enhance growth and profitability, with a focus on driving new product development and expanding the sales force [15][48] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the U.S. spine market and anticipates continued growth in both domestic and international markets [70] - The company expects to achieve revenue growth in the range of 13.5% to 15.1% for 2025, with non-GAAP earnings per share guidance increased to between $3.75 and $3.85 [34][35] - Management highlighted the importance of maintaining operational excellence while pursuing organic growth opportunities [72] Other Important Information - The company has been active in share repurchases, spending $40 million in Q3 2025, with a total of $256 million year-to-date [5][31] - Research and development expenses were $38.1 million, or 4.9% of sales, reflecting a decline due to synergy capture [27] - SG&A expenses included one-time litigation charges of $28.3 million, impacting the overall expense ratio [29] Q&A Session Summary Question: What is driving the strength and acceleration in U.S. Core Spine? - Management noted 32 weeks of consecutive sales growth, with broad strength across all categories, driven by competitive recruiting and new product launches [38][39] Question: What are the expectations for Nevro's margin progression? - Nevro's EBITDA margin was 16.2%, with plans to drive efficiency and growth through better product development and sales force integration [46][48] Question: How is the enabling tech business expected to perform in Q4? - Management expressed confidence in the pipeline, indicating potential for strong revenue generation despite recent slower sales [50][51] Question: What are the plans for Nevro's product portfolio? - Future developments may include expanding into peripheral nerve treatments and addressing conditions like diabetic neuropathy and Parkinson's tremors [55][56] Question: What is the strategy regarding flexible payment models? - The company is seeing an increase in requests for flexible capital acquisition models, which may affect revenue recognition timing [42][57]

Sales Performance - Total net sales for the three months ended September 30, 2025, were $769.0 million, an increase of $143.3 million or 22.9% compared to $625.7 million in the same period of 2024[159]. - Net sales in the United States increased by $121.8 million, or 24.6%, driven by Nevro sales of $83.3 million and Musculoskeletal Solutions and Neuromonitoring sales of $48.4 million[159]. - International net sales increased by $21.5 million, or 16.5%, primarily due to Nevro sales of $15.9 million and an increase in Musculoskeletal Solutions spine product sales of $6.0 million[160]. - Total net sales increased by $250.4 million, or 13.5%, to $2.1 billion for the nine months ended September 30, 2025, driven by a $224.1 million increase in U.S. sales[173]. - International net sales rose by $26.3 million, or 6.9%, for the nine months ended September 30, 2025, with significant contributions from the Europe and Middle East region[174]. Cost and Expenses - Cost of sales decreased by $18.0 million, or 6.6%, to $252.5 million, with the percentage of net sales dropping to 32.8% from 43.2%[162]. - Cost of sales decreased by $75.3 million, or 9.8%, to $696.7 million for the nine months ended September 30, 2025, resulting in a cost of sales percentage of 33.0%[175]. - Research and development expenses increased by $2.7 million, or 7.6%, to $38.1 million, representing 4.9% of net sales[163]. - Research and development expenses decreased by $19.3 million, or 14.8%, to $111.1 million for the nine months ended September 30, 2025, representing 5.3% of net sales[176]. - Selling, general and administrative expenses rose by $73.6 million, or 30.6%, to $313.6 million, accounting for 40.8% of net sales[164]. - Selling, general and administrative expenses increased by $131.8 million, or 18.1%, to $860.0 million for the nine months ended September 30, 2025, accounting for 40.7% of net sales[177]. - Acquisition-related costs surged by $18.9 million, or 151.3%, to $31.5 million for the nine months ended September 30, 2025, primarily due to costs associated with the Nevro Merger[179]. - Restructuring costs decreased by $9.9 million, or 41.5%, to $13.9 million for the nine months ended September 30, 2025, representing 0.7% of net sales[180]. Income and Tax - A bargain purchase gain of $3.8 million was recorded due to adjustments related to the Nevro Merger, representing 0.5% of net sales[168]. - The company reported a bargain purchase gain of $114.4 million for the nine months ended September 30, 2025, attributed to the Nevro Merger[181]. - The income tax provision increased by $19.8 million, or 381.7%, to $25.0 million for the three months ended September 30, 2025, with an effective tax rate of 17.4%[170]. Cash Flow and Financing - Net cash provided by operating activities for the nine months ended September 30, 2025, was $504.86 million, an increase of $194.56 million compared to $310.30 million in 2024[187]. - Cash used in investing activities increased by $171.64 million, primarily due to acquisition-related costs of $234.9 million[189]. - Net cash used in financing activities was $692.38 million, largely due to the repayment of senior convertible notes amounting to $450 million[190]. - The company reported a net income increase of $320.8 million, contributing to higher cash from operating activities[188]. - The effect of foreign exchange rate changes on cash was an increase of $18.41 million for the nine months ended September 30, 2025[187]. - The company experienced a decrease in cash and cash equivalents of $412.67 million for the nine months ended September 30, 2025[187]. - The company has no outstanding borrowings under the September 2023 Credit Agreement as of September 30, 2025[186]. - The company is subject to financial covenants, including a funded net indebtedness to adjusted EBITDA ratio[186]. Mergers and Acquisitions - The Nevro Merger was completed on April 3, 2025, with Nevro's common stock converted into cash at $5.85 per share[150]. - The company entered into a revolving credit facility of up to $400 million with a termination date of September 27, 2028[186]. - The company acquired additional obligations and commitments related to the NuVasive and Nevro mergers, including contingent consideration arrangements and senior convertible notes[192]. - International net sales accounted for approximately 19.4% of total net sales during the nine months ended September 30, 2025[155]. - The company plans to expand its U.S. sales force to strengthen its market position[154].

Financial Performance - Q3 2025 revenue increased by 23% to $769.0 million, with U.S. Spine business growing by 10%[3] - GAAP net income for Q3 2025 was $119.0 million, a 129.5% increase year-over-year, driven by higher sales of $143.3 million[4] - Non-GAAP diluted EPS for Q3 2025 was $1.18, up 42.6% compared to $0.83 in Q3 2024[4] - Net income for Q3 2025 reached $118,966,000, a significant increase from $51,836,000 in Q3 2024, representing a growth of 129%[24] - The company reported a net income of $397.274 million for the nine months ended September 30, 2025, compared to $76.479 million in 2024, marking a significant increase of 419.5%[18] - The company’s diluted earnings per share for the nine months ended September 30, 2025, was $2.90, compared to $0.56 in 2024[18] Cash Flow and Guidance - Record non-GAAP free cash flow of $213.9 million in Q3 2025, a 24% increase quarter-over-quarter[3] - The company raised its full-year 2025 revenue guidance to $2.86 to $2.90 billion from $2.80 to $2.90 billion[6] - Non-GAAP fully diluted EPS guidance for 2025 increased to $3.75 to $3.85 from $3.00 to $3.30[6] - Free cash flow for the nine months ended September 30, 2025, was $386,378,000, an increase from $211,981,000 in the same period of 2024[38] Sales and Market Performance - International net sales grew by 16.5% year-over-year, with a 13.5% increase on a constant currency basis[3] - The Nevro acquisition contributed $99.3 million to sales, exceeding expectations and supporting future growth[4] - Base business net sales, excluding Nevro, were $669.8 million, reflecting a 7.0% increase[7] - Net sales for Q3 2025 reached $769.048 million, a 22.9% increase from $625.705 million in Q3 2024[20] - The company’s musculoskeletal solutions segment generated $741.009 million in sales for Q3 2025, up from $587.402 million in Q3 2024[20] - Net sales of Nevro products for Q3 2025 were $99,254,000, contributing to the overall sales growth[41] Profitability Metrics - Adjusted EBITDA for Q3 2025 was $252,601,000, compared to $193,691,000 in Q3 2024, reflecting a year-over-year increase of 30.4%[24] - Gross profit margin for Q3 2025 improved to 64.2%, compared to 53.0% in Q3 2024[33] - The adjusted gross profit for Q3 2025 was $523,472,000, with an adjusted gross profit margin of 68.1%[33] - The company reported a net income margin of 15.5% for Q3 2025, compared to 8.3% in Q3 2024[24] Expenses and Liabilities - Research and development expenses increased to $111.083 million for the nine months ended September 30, 2025, from $130.346 million in the same period of 2024[18] - Cash and cash equivalents decreased to $371.769 million as of September 30, 2025, down from $784.438 million at the end of 2024[21] - Total current assets were $1.924 billion as of September 30, 2025, compared to $2.177 billion at the end of 2024[17] - The company’s total liabilities decreased to $696.815 million as of September 30, 2025, from $1.074 billion at the end of 2024[17] - The company incurred merger and acquisition-related costs of $4,678,000 in Q3 2025, down from $61,160,000 in Q3 2024[28] Operating Performance - Operating income for the nine months ended September 30, 2025, was $310.476 million, compared to $105.717 million for the same period in 2024, representing a 194.5% increase[18] - Comprehensive income for the nine months ended September 30, 2025, was $415.062 million, compared to $79.708 million in 2024[18]

Core Insights - Globus Medical, Inc. reported a strong financial performance for Q3 2025, with revenue increasing by 23% year-over-year, driven by a 10% growth in the US Spine business and strong demand across products and geographies [2][3] - The company achieved record non-GAAP free cash flow of $213.9 million, up 24% quarter-over-quarter, and non-GAAP diluted earnings per share of $1.18, a 43% increase compared to the same quarter last year [2][4] - The company raised its full-year 2025 revenue guidance to a range of $2.86 to $2.90 billion and non-GAAP fully diluted earnings per share to a range of $3.75 to $3.85, indicating confidence in future growth [5] Financial Performance - Worldwide net sales for Q3 2025 were $769.0 million, a 22.9% increase from Q3 2024, with US net sales rising by 24.6% and international sales increasing by 16.5% [2][7] - GAAP net income for Q3 2025 was $119.0 million, reflecting a 129.5% increase year-over-year, primarily due to higher sales, including $99.3 million from the Nevro acquisition [3][7] - Non-GAAP diluted EPS for Q3 2025 was $1.18, up 42.6% from $0.83 in Q3 2024 [3][40] Cash Flow and Capital Management - Net cash provided by operating activities was $249.7 million for Q3 2025, contributing to a non-GAAP free cash flow of $213.9 million [4][43] - The company executed share repurchases totaling $40 million in the quarter, bringing the total for the first nine months of 2025 to $255.5 million, demonstrating a commitment to shareholder value [2][4] Strategic Acquisitions - The integration of the recently acquired Nevro business has exceeded expectations, contributing significantly to revenue growth and underscoring the effectiveness of the company's integration strategy [2][3] - The Nevro acquisition is expected to be accretive to earnings in 2025, further enhancing the company's growth prospects [5] Market Position and Outlook - The company remains focused on achieving consistent organic growth through innovation and disciplined execution, aiming to finish 2025 strong [2][5] - The strong performance in Q3 highlights the company's ability to balance growth with operational efficiency and synergy execution [2][3]

Core Insights - Rigetti Computing (RGTI) is set to release its third-quarter 2025 results on November 10, with expectations of a loss per share of 5 cents and revenues of $2.39 million, reflecting a modest year-over-year improvement of 0.4% [1][2][9] Group 1: Financial Performance - The Zacks Consensus Estimate for RGTI's revenues is $2.39 million, indicating a 0.4% year-over-year increase, while the loss per share is projected at 5 cents, representing a 37.5% growth compared to the same quarter last year [2] - In the last reported quarter, RGTI's loss per share of 5 cents exceeded the Zacks Consensus Estimate by 16.7%, although the company has experienced an average earnings surprise of negative 10.8% over the past four quarters [1][2] Group 2: Influencing Factors - Ongoing uncertainty regarding U.S. public-sector funding is likely to impact RGTI's third-quarter earnings, particularly due to the expiration of the National Quantum Initiative and pending congressional reauthorization [3] - The deployment of Cepheus-1-36Q, the largest multichip quantum computer, is expected to enhance RGTI's strategic momentum and may support incremental platform revenue as early adopters explore hybrid quantum workflows [4] - RGTI's strengthened balance sheet, bolstered by a $350 million equity raise, provides the company with approximately $571.6 million in cash and no debt, allowing for continued R&D and system-scaling projects [5] Group 3: Future Outlook - The dynamics surrounding NQCC and DARPA present potential catalysts for RGTI's earnings, with advancements in U.K. programs and confidence in selection for DARPA's Quantum Benchmarking Initiative [6] - Overall, RGTI's third-quarter earnings are expected to be characterized by constrained revenue due to federal funding timing, but supported by accelerated platform deployment and strategic partnerships [7]

Core Viewpoint - Wall Street analysts predict that Globus Medical (GMED) will report quarterly earnings of $0.79 per share, reflecting a year-over-year decline of 4.8%, while revenues are expected to reach $733.45 million, marking a 17.2% increase compared to the same quarter last year [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been revised downward by 1.3%, indicating a collective reassessment by covering analysts [2]. - Revisions to earnings estimates are crucial as they serve as significant indicators for predicting potential investor actions regarding the stock [3]. Revenue Projections - Analysts expect 'Net Sales by Product Category - Enabling Technologies' to be $40.23 million, showing a year-over-year increase of 5% [5]. - The consensus for 'Net Sales by Product Category - Musculoskeletal Solutions' is projected at $693.98 million, reflecting an 18.1% increase from the prior-year quarter [5]. - The average prediction for 'Geographic Revenues - International' is $144.37 million, indicating an 11.1% increase from the year-ago quarter [6]. - 'Geographic Revenues - United States' are forecasted to reach $589.84 million, representing a 19% increase from the prior-year quarter [6]. Stock Performance - Globus Medical shares have increased by 4% over the past month, outperforming the Zacks S&P 500 composite, which has seen a 1% increase [6]. - The company holds a Zacks Rank 3 (Hold), suggesting it is expected to closely follow overall market performance in the near term [6].

Core Insights - McKesson Corporation (MCK) is set to report its second-quarter fiscal 2026 results on November 5, with expectations of a solid performance following a strong start to the year, where revenues increased by 23% year over year to $97.8 billion and adjusted earnings per share (EPS) rose by 5% to $8.26 [2][3] Financial Performance - The upcoming quarterly results are anticipated to show a more normalized pace of growth compared to the first quarter, which was boosted by acquisitions and specialty drug volumes [3] - The Zacks Consensus Estimate for earnings is $8.92 per share, reflecting a 26.2% year-over-year improvement, while revenue estimates are pegged at $104.66 billion, indicating an 11.8% year-over-year increase [6][10] Segment Performance - The U.S. Pharmaceutical segment, McKesson's largest business, is expected to remain the primary growth driver, with revenues in the first quarter surging by 25.4% to $90 billion, supported by prescription volume growth and strong GLP-1 medication sales [7][8] - The Prescription Technology Solutions (RxTS) segment is projected to continue its growth trajectory, with revenues expected to increase by 7.4% to $1.36 billion, driven by high prior authorization volumes and expanding business [11][12] - The Medical-Surgical Solutions segment is likely to maintain modest growth of 2-6%, while international operations are expected to see limited growth due to divestitures impacting sales [13][14] Operational Efficiency - McKesson's broad-based strength is attributed to expanding specialty pharmaceutical demand, effective execution in oncology and multi-specialty services, and digital access solutions that enhance medication affordability [4] - Automation initiatives and disciplined cost management are expected to support margins, despite potential headwinds from higher operating costs related to recent acquisitions [5][10] Earnings Outlook - The model predicts an earnings beat for McKesson this earnings season, supported by a positive Earnings ESP of +1.16% and a Zacks Rank of 1 (Strong Buy) [15][16]

Core Insights - DENTSPLY SIRONA Inc. is set to report its third-quarter 2025 results on November 6, with expectations of mixed performance due to various market pressures [2][4]. Financial Performance - The Zacks Consensus Estimate for revenues is $901.6 million, while earnings are expected to be 45 cents per share. The company's own estimates are slightly higher for revenues at $904 million but lower for earnings at 42 cents per share [3]. - In the previous quarter, the company reported a 4.9% year-over-year decline in sales to $936 million, primarily due to weaknesses in Orthodontic & Implant Solutions and Connected Technology Solutions [5]. Market Conditions - The company is facing tariff-related cost pressures, subdued U.S. demand, and ongoing product transitions, which are expected to impact both revenues and margins in the upcoming quarter [4][6]. - Management has maintained its full-year outlook, indicating confidence in its cost structure despite the challenges [6]. Segment Analysis - **Essential Dental Solutions (EDS)**: Expected to show modest low-single-digit growth, with revenues estimated to decline 0.5% organically to $370.5 million, supported by stable patient traffic globally [7]. - **Orthodontic & Implant Solutions (OIS)**: Anticipated to be a significant drag, with a projected 19.7% organic revenue decline to $195.2 million, impacted by the phase-out of the Byte aligner business and weak implant demand [8][10]. - **Connected Technology Solutions (CTS)**: Expected to face continued weakness, with revenues estimated to decline 2.8% organically to $264.4 million, as U.S. dental offices reduce capital equipment purchases [11]. - **Wellspect Healthcare**: Projected to stabilize with a 0.9% organic revenue increase to $73.9 million, supported by new product introductions [12]. Earnings Prediction - The current model does not predict an earnings beat for DENTSPLY SIRONA, with an Earnings ESP of -2.46% and a Zacks Rank of 3 (Hold) [13][14].

Leadership Changes - Accuray has appointed Steve La Neve as CEO, effective immediately, as part of a transformation plan aimed at expanding margins and improving competitiveness [2][3] - La Neve succeeds Suzanne Winter, who will retire after six years but will remain in an advisory role until November [2] Strategic Initiatives - The company plans to implement organizational, strategic, and operational actions during the current fiscal year ending in June to drive sustainable, profitable growth [2] - Steven Mayer has been named as the transformation board sponsor to collaborate with La Neve and the management team [4] Financial Performance - Accuray reported preliminary fiscal first-quarter 2026 results, showing an adjusted loss before interest, tax, depreciation, and amortization of approximately $4 million, with revenue between $92.5 million and $94 million [5] - For fiscal year 2025, Accuray reported a loss of $1.6 million, a significant improvement from a net loss of $15.5 million in the previous fiscal year, with a 3% year-over-year revenue increase to $458.5 million [5] Market Challenges - The company has faced challenges over the past year, including slower order demand in the U.S. as hospitals delayed replacing capital equipment [6]

Company Overview - Globus Medical (GMED) is currently trading approximately 33% below its 1-year high and has a price-to-sales (PS) multiple that is below the average of the past 3 years, indicating potential value [2] - The company specializes in healthcare solutions for musculoskeletal disorders and orthopedic trauma treatment, offering products such as fracture plates, compression screws, intramedullary nails, and external fixation systems globally [3] Financial Performance - The company has demonstrated reasonable revenue growth, with a last twelve months (LTM) growth rate of 17.4% and a 3-year average growth rate of 44.7% [6] - GMED has a free cash flow margin of almost 19.9% and an operating margin of 13.2% for the LTM, showcasing its cash-generative capabilities [6] - The stock is trading at a price-to-earnings (PE) multiple of 23.8, which is considered modest given its encouraging fundamentals [6] Market Comparison - Compared to the S&P 500, GMED shows a lower valuation, enhanced revenue growth, but reduced margins, suggesting a competitive position in the market [6] - The average forward returns for GMED are 12.7% over 6 months and 25.8% over 12 months, with a win rate of over 70% for both periods [7] Historical Volatility - The stock has experienced significant declines in the past, including a 34% drop during the 2018 correction, a 41% decline during the Covid pandemic, and a nearly 48% fall during the inflation shock, indicating susceptibility to market downturns [8] - Despite strong fundamentals, the stock can be adversely impacted during tumultuous periods, highlighting the importance of market conditions in stock performance [8]